Amphastar Pharmaceuticals, Inc. AMPH
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- +3.51%
- 1 year
- +12.41%
- Open
- 27.12
- Prev close
- 26.93
- Mkt cap
- 1.18B
- Vol
- 664.51K
- Avg vol
- 461.35K
- EPS
- 1.69
- P/E
- 16.40
- Div yield
- 0.00%
More statistics
- Low
- 26.76
- High
- 27.76
- Forward P/E
- 8.66
- Beta
- 0.90
- Short ratio
- 8.22
- Inst. own
- 68.40%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 24.64
- 200-d avg
- 22.25
- 1y target
- 22.50
15m chart
Built from the cached five-day intraday bars.
Signals (40)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Oct 30, 3:40 PM | 1 day ago |
| SMA: Bullish | Oct 30, 3:40 PM | 1 day ago |
| SMA: Bearish | Oct 30, 3:25 PM | 1 day ago |
| SMA: Bearish | Oct 30, 2:10 PM | 1 day ago |
| MACD: Sell Signal | Oct 30, 2:10 PM | 1 day ago |
| SMA: Bullish | Oct 30, 1:55 PM | 1 day ago |
| SMA: Bearish | Oct 30, 1:40 PM | 1 day ago |
| RSI: Overbought | Oct 30, 11:40 AM | 1 day ago |
| MACD: Buy Signal | Oct 30, 11:25 AM | 1 day ago |
| SMA: Bullish | Oct 30, 11:10 AM | 1 day ago |
| SMA: Bearish | Oct 30, 10:10 AM | 1 day ago |
| MACD: Sell Signal | Oct 30, 10:10 AM | 1 day ago |
| MACD: Buy Signal | Oct 30, 9:40 AM | 1 day ago |
| RSI: Overbought | Oct 30, 9:40 AM | 1 day ago |
| RSI: Overbought | Oct 29, 3:35 PM | 2 days ago |
| SMA: Bullish | Oct 29, 2:20 PM | 2 days ago |
| SMA: Bullish | Oct 29, 1:15 PM | 2 days ago |
| SMA: Bearish | Oct 29, 12:35 PM | 2 days ago |
| MACD: Sell Signal | Oct 29, 12:35 PM | 2 days ago |
| RSI: Overbought | Oct 29, 10:40 AM | 2 days ago |
| RSI: Overbought | Oct 29, 10:15 AM | 2 days ago |
| MACD: Buy Signal | Oct 28, 3:55 PM | 3 days ago |
| RSI: Overbought | Oct 28, 3:55 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:05 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 1:00 PM | 3 days ago |
| SMA: Bearish | Oct 28, 12:30 PM | 3 days ago |
| RSI: Overbought | Oct 28, 10:25 AM | 3 days ago |
| SMA: Bullish | Oct 27, 3:45 PM | 4 days ago |
| SMA: Bearish | Oct 27, 3:30 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:25 PM | 4 days ago |
| SMA: Bearish | Oct 27, 1:15 PM | 4 days ago |
| SMA: Bullish | Oct 27, 12:50 PM | 4 days ago |
| SMA: Bullish | Oct 27, 12:50 PM | 4 days ago |
| SMA: Bearish | Oct 27, 12:20 PM | 4 days ago |
| SMA: Bearish | Oct 27, 12:20 PM | 4 days ago |
| SMA: Bullish | Oct 27, 12:05 PM | 4 days ago |
| SMA: Bullish | Oct 27, 11:45 AM | 4 days ago |
| SMA: Bearish | Oct 27, 11:00 AM | 4 days ago |
| SMA: Bullish | Oct 26, 3:55 PM | 5 days ago |
| SMA: Bearish | Oct 26, 12:35 PM | 5 days ago |
Key statistics
- Market cap
- 1.17B
- Enterprise value
- 1.54B
- Trailing P/E
- 16.24
- Forward P/E
- 8.66
- PEG ratio
- 0.00
- Price / sales
- 1.60
- Price / book
- 1.52
- EPS (TTM)
- 1.69
- Beta
- 0.90
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 10.76%
- Revenue (TTM)
- 730.02M
- Revenue growth
- 5.40%
- Free cash flow
- 230.10M
- Total cash
- 290.12M
- Total debt
- 688.32M
- Return on equity
- 10.30%
- Shares outstanding
- 42.54M
- Short % of float
- 22.20%
- 50-day average
- 24.64
- 200-day average
- 22.25
Analyst view
Consensus: hold
- Target (low)
- 20.00
- Target (mean)
- 22.50
- Target (high)
- 30.00
- Strong buy0
- Buy0
- Hold6
- Sell0
- Strong sell1
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate 0.85867.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | 0.864 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | 0.62 | 0.91 | +0.29 | +46.77% |
| May 7, 2026 | Mar 31, 2026 | 0.70 | 0.42 | -0.28 | -40.00% |
| Feb 26, 2026 | Dec 31, 2025 | 0.903 | 0.73 | -0.17 | -19.16% |
| Nov 6, 2025 | Sep 30, 2025 | 0.77 | 0.93 | +0.16 | +20.78% |
| Aug 7, 2025 | Jun 30, 2025 | 0.71 | 0.85 | +0.14 | +19.72% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 18, 2026 | Barclays | main | Equal-Weight | Equal-Weight |
| Aug 7, 2026 | Piper Sandler | main | Neutral | Neutral |
| Aug 7, 2026 | Wells Fargo | main | Equal-Weight | Equal-Weight |
| Jun 29, 2026 | B of A Securities | down | Neutral | Underperform |
| Jun 3, 2026 | Barclays | main | Equal-Weight | Equal-Weight |
| May 14, 2026 | Wells Fargo | down | Overweight | Equal-Weight |
About Amphastar Pharmaceuticals, Inc.
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; and emergency syringe products, including atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate. In addition, it offers Albuterol sulfate inhalation aerosol for the treatment or prevention of bronchospasm; Iron sucrose injection, an iron replacement product for the treatment of iron deficiency anemia in patients with chronic kidney disease; Teriparatide injection for managing daily osteoporosis therapy; and Ipratropium Bromide HFA inhalation aerosol, an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. Further, the company provides active pharmaceutical ingredient (API) products, such as Recombinant Human Insulin and porcine insulin API. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- amphastar.com
News
- Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for
- Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 5, 2026
- Should Value Investors Buy Amphastar Pharmaceuticals (AMPH) Stock?
- Comparing Enanta Pharmaceuticals (NASDAQ:ENTA) and Amphastar Pharmaceuticals (NASDAQ:AMPH)
- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Receives Average Rating of “Reduce” from Analysts
- Insider Selling: Amphastar Pharmaceuticals (NASDAQ:AMPH) EVP Sells $239,400.00 in Stock
- Amphastar Pharmaceuticals to Present at the Wells Fargo 21st Annual Healthcare Conference
- 3 Generic Drug Stocks to Watch Amid Improving Industry Trends
- 12 Health Care Stocks Moving In Monday's After-Market Session
- New Strong Sell Stocks for August 14th
Your note
Sign in to keep a note on AMPH — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DEFLIN GAYLE | Director | Stock Award(Grant) | May 31, 2026 | 19,057 |
| GERST DIANE G. | Director | Stock Award(Grant) | May 31, 2026 | 31,899 |
| LEE HOWARD S | Director | Stock Award(Grant) | May 31, 2026 | 159,350 |
| LIAWATIDEWI YAKOB | Officer and Director | Stock Award(Grant) | Mar 8, 2026 | 125,384 |
| PETERS WILLIAM J | Chief Financial Officer | Sale | Sep 20, 2026 | 168,707 |
| PETERSEN FLOYD F | Director | Sale | Dec 11, 2025 | 71,368 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 12.28% | 5,224,934 | 143.42M | Jun 29, 2026 |
| Dimensional Fund Advisors LP | 5.42% | 2,305,107 | 63.28M | Jun 29, 2026 |
| State Street Corporation | 3.86% | 1,642,126 | 45.08M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 3.48% | 1,481,952 | 40.68M | Jun 29, 2026 |
| American Century Companies Inc | 2.77% | 1,176,626 | 32.30M | Jun 29, 2026 |
| Marshall Wace LLP | 2.51% | 1,066,322 | 29.27M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 4.40% | 1,873,133 | 51.42M | Sep 29, 2026 |
| American Century ETF Trust-Avantis U.S. Small Cap Value ETF | 3.06% | 1,303,435 | 35.78M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.48% | 1,055,676 | 28.98M | Jun 29, 2026 |
| Capitol Series Trust-FullerThaler Behavioral Small-Cap Equity Fund | 2.12% | 902,737 | 24.78M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.97% | 839,366 | 23.04M | Sep 29, 2026 |
| DFA INVESTMENT DIMENSIONS GROUP INC-U.S. Small Cap Value Portfolio | 1.40% | 596,077 | 16.36M | Jul 30, 2026 |